CorMedix Inc (CRMD) - Net Assets
Based on the latest financial reports, CorMedix Inc (CRMD) has net assets worth $405.31 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($826.14 Million) and total liabilities ($420.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of CorMedix Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $405.31 Million |
| % of Total Assets | 49.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | 545.41% |
| 10-Year Change | 2175.15% |
| Growth Volatility | 260.02 |
CorMedix Inc - Net Assets Trend (2008–2025)
This chart illustrates how CorMedix Inc's net assets have evolved over time, based on quarterly financial data. See CorMedix Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for CorMedix Inc (2008–2025)
The table below shows the annual net assets of CorMedix Inc from 2008 to 2025. For live valuation and market cap data, see how much is CorMedix Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $405.31 Million | +378.76% |
| 2024-12-31 | $84.66 Million | +20.69% |
| 2023-12-31 | $70.14 Million | +27.39% |
| 2022-12-31 | $55.06 Million | -12.32% |
| 2021-12-31 | $62.80 Million | +42.00% |
| 2020-12-31 | $44.22 Million | +87.02% |
| 2019-12-31 | $23.65 Million | +379.23% |
| 2018-12-31 | $4.93 Million | -31.41% |
| 2017-12-31 | $7.19 Million | -59.62% |
| 2016-12-31 | $17.81 Million | -47.62% |
| 2015-12-31 | $34.01 Million | +835.80% |
| 2014-12-31 | $3.63 Million | +190.36% |
| 2013-12-31 | $-4.02 Million | -746.14% |
| 2012-12-31 | $-475.38K | -138.44% |
| 2011-12-31 | $1.24 Million | -82.96% |
| 2010-12-31 | $7.26 Million | +149.33% |
| 2009-12-31 | $-14.71 Million | -22.30% |
| 2008-12-31 | $-12.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CorMedix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15936541200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $79.00K | 0.02% |
| Other Comprehensive Income | $3.00K | 0.00% |
| Other Components | $581.80 Million | 143.55% |
| Total Equity | $405.31 Million | 100.00% |
CorMedix Inc Competitors by Market Cap
The table below lists competitors of CorMedix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ashot Ashkelon Industries Ltd
TA:ASHO
|
$601.01 Million |
|
Rongcheer Industrial Technology (Suzhou) Co. Ltd. A
SHE:301360
|
$601.48 Million |
|
Northern Data AG
XETRA:NB2
|
$601.55 Million |
|
Tamar Petroleum Ltd
TA:TMRP
|
$601.82 Million |
|
Gresgying Digital Energy Technology Co Ltd
SHG:600212
|
$600.82 Million |
|
YoungPoong
KO:000670
|
$600.75 Million |
|
Mega-info Media Co.Ltd.
SHE:301102
|
$600.64 Million |
|
Momentum Group AB (publ)
ST:MMGR-B
|
$600.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CorMedix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 84,656,950 to 405,307,000, a change of 320,650,050 (378.8%).
- Net income of 163,055,000 contributed positively to equity growth.
- New share issuances of 90,158,000 increased equity.
- Other comprehensive income decreased equity by 87,646.
- Other factors increased equity by 67,524,696.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $163.06 Million | +40.23% |
| Share Issuances | $90.16 Million | +22.24% |
| Other Comprehensive Income | $-87.65K | -0.02% |
| Other Changes | $67.52 Million | +16.66% |
| Total Change | $- | 378.76% |
Book Value vs Market Value Analysis
This analysis compares CorMedix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-71.41 | $8.67 | x |
| 2009-12-31 | $-85.85 | $8.67 | x |
| 2010-12-31 | $3.83 | $8.67 | x |
| 2011-12-31 | $0.54 | $8.67 | x |
| 2012-12-31 | $-0.21 | $8.67 | x |
| 2013-12-31 | $-1.45 | $8.67 | x |
| 2014-12-31 | $0.85 | $8.67 | x |
| 2015-12-31 | $5.43 | $8.67 | x |
| 2016-12-31 | $2.35 | $8.67 | x |
| 2017-12-31 | $-13.80 | $8.67 | x |
| 2018-12-31 | $-10.05 | $8.67 | x |
| 2019-12-31 | $-8.09 | $8.67 | x |
| 2020-12-31 | $1.55 | $8.67 | x |
| 2021-12-31 | $1.67 | $8.67 | x |
| 2022-12-31 | $1.37 | $8.67 | x |
| 2023-12-31 | $1.38 | $8.67 | x |
| 2024-12-31 | $1.44 | $8.67 | x |
| 2025-12-31 | $5.05 | $8.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CorMedix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 40.23%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 52.31%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 2.04x
- Recent ROE (40.23%) is above the historical average (-91.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.79 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.65 Million |
| 2010 | -150.31% | 0.00% | 0.00x | 1.22x | $-11.63 Million |
| 2011 | -542.75% | 0.00% | 0.00x | 2.07x | $-6.83 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.38 Million |
| 2013 | 0.00% | -456654.90% | 0.00x | 0.00x | $-8.73 Million |
| 2014 | -562.76% | -10806.25% | 0.04x | 1.40x | $-20.82 Million |
| 2015 | -53.47% | -8655.37% | 0.01x | 1.09x | $-21.59 Million |
| 2016 | -138.33% | -10996.46% | 0.01x | 1.23x | $-26.43 Million |
| 2017 | 0.00% | -10023.45% | 0.02x | 0.00x | $-17.79 Million |
| 2018 | 0.00% | -6242.40% | 0.02x | 0.00x | $-8.93 Million |
| 2019 | 0.00% | -5801.29% | 0.01x | 0.00x | $3.11 Million |
| 2020 | -49.81% | -9207.70% | 0.00x | 1.11x | $-26.45 Million |
| 2021 | -44.92% | -14774.70% | 0.00x | 1.10x | $-34.49 Million |
| 2022 | -53.94% | -45409.90% | 0.00x | 1.13x | $-35.21 Million |
| 2023 | -66.06% | 0.00% | 0.00x | 1.17x | $-53.35 Million |
| 2024 | -21.18% | -41.24% | 0.37x | 1.40x | $-26.40 Million |
| 2025 | 40.23% | 52.31% | 0.38x | 2.04x | $122.52 Million |
Industry Comparison
This section compares CorMedix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CorMedix Inc (CRMD) | $405.31 Million | 0.00% | 1.04x | $600.87 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more